Unveilling the antidiabetic potential of ashwagandha (Withania somnifera L.) and its withanolides-a review – PubMed Black Hawk Supplements

Abstract

Withania somnifera, commonly known as Ashwagandha, is a prominent herb in Ayurvedic medicine, recognised for its diverse pharmacological properties, particularly its potential anti-diabetic effects. With the global incidence of diabetes mellitus (DM) surpassing 366 million, interest in herbal remedies like Ashwagandha has surged. Active compounds known as withanolides have demonstrated efficacy in modulating glucose homeostasis and enhancing insulin sensitivity. Systematic reviews indicate that Ashwagandha effectively restores altered blood glucose and glycosylated haemoglobin (HbA1c) levels without significant safety concerns. Animal studies reveal hypoglycaemic effects from both root and leaf extracts, improving metabolic parameters. Although clinical evidence remains limited, existing trials suggest that Ashwagandha may enhance insulin sensitivity and overall metabolic profiles in diabetic patients. This review underscores the potential of Ashwagandha as a complementary approach in DM management, warranting further research to confirm its therapeutic benefits and elucidate underlying mechanisms.

Keywords: Ashwagandha; Vos viewer network visualisation; diabetes mellitus; withanolides.

Publication types